Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab With Mezigdomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT07901868Phase 2Not yet recruiting
- Sponsor
- Fundación PETHEMA
- Start
- Nov 2026
- Primary completion
- Dec 2031
- Countries
- 1
01
Overview
A Phase 2 trial of elranatamab, mezigdomide in multiple myeloma (MM), sponsored by Fundación PETHEMA. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
elranatamabmezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07901868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07901868.